Teva Will Appeal Patent Ruling On P&G's Actonel
Teva announced on Friday that it would appeal the U.S. District Court for the District of Delaware's ruling that the Procter & Gamble patent was valid.
Teva had stipulated earlier in the case that the manufacture and marketing of its generic tablets for risedronate sodium, Actonel's active ingredient, would infringe the patent's claims.
Judge Joseph Farnan affirmed the validity...
To view the full article, register now.